Friday, 20 Oct 2017

You are here

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

  1. ARTIS RA registry shows those initiating a TNFi within 5 yrs of onset double their odds of returning to work in 3 yrs https://t.co/WytSlSYRj1
  2. ARTIS & DANBIO registries: 8703 SpA (AS, PsA) patients treated with TNFI: they do NOT have an increase risk of cancer overall; nor the 6 most common types CA http://buff.ly/2icvD9O
  3. Hepatosplenic T cell lymphoma: review shows this to be a very rare event with TNFi; but is more common in IBD pts (younger), receiving thiopurines. http://buff.ly/2jn7Bqm
  4. Biosimilar Inflectra priced at only a 15% discount; CMS issues payment and claims processing information https://t.co/lCwn198PAN
  5. There is no interaction between low dose weekly MTX and NSAIDs, PCNs or PPIs. https://t.co/h4JeLoSbEg
  6. FDA reviewing a new drug application (NDA) for the new combo drug: allopurinol + lesinurad (Ironwood Pharm) to Rx hyperuricemia and uncontrolled gout https://t.co/e95R8TlXuv
  7. Meta-analysis of 1069 knee OA patients- intraarticular Platelet Rich Plasma (vs HA, NS) shows significantly better WOMAC pain/function scores. @12mo https://t.co/LBJt2SbZXO,
  8. Chronic PPI use associated with 74% more C difficile infections & 2.5-fold increased risk of recurrent C difficile with chronic PPI https://t.co/W1mLbPEPYP
  9. 13% of US African Americans have diabetes; but AA are seldom included in diabetes clinical trials. Whatsupwiththat? https://t.co/GYgXnAcyzb
  10. Total knee vs hemiarthroplasty show equal outcomes;more complications with bilateral total knee replacements (pt selection is critical to the success of hemiarthroplasty) https://t.co/D8OXH8VnTA
  11. 94 pts with MTX pancytopenia in elderly; 24% mortality; risk factors include age>65, sepsis + hypoalbuminemia https://t.co/7p99v9bt3g
  12. Multiple Comorbidity Risks with Giant Cell Arteritis
  13. Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death? 
  14. The IL-6 Wars 
  15. DMARDs Under Study for Secondary Prevention of Cardiovascular Events

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.